Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 6.3% – Here’s What Happened

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL)’s stock price traded up 6.3% on Monday . The company traded as high as $2.25 and last traded at $2.2850. Approximately 381,911 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 1,748,486 shares. The stock had previously closed at $2.15.

Wall Street Analyst Weigh In

AUTL has been the topic of a number of research analyst reports. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Finally, Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Autolus Therapeutics Stock Up 0.4%

The firm has a 50-day moving average price of $1.67 and a two-hundred day moving average price of $1.58. The company has a market capitalization of $609.51 million, a P/E ratio of -2.16 and a beta of 2.07. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The business had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Equities research analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several large investors have recently added to or reduced their stakes in AUTL. Invesco Ltd. grew its holdings in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares in the last quarter. Jane Street Group LLC increased its holdings in Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after buying an additional 91,222 shares during the period. Geode Capital Management LLC increased its holdings in Autolus Therapeutics by 90.5% in the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after buying an additional 78,058 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Autolus Therapeutics by 2,891.7% in the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock valued at $2,223,000 after buying an additional 942,540 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.